2O53
Crystal structure of apo-Aspartoacylase from human brain
2O53 の概要
| エントリーDOI | 10.2210/pdb2o53/pdb |
| 関連するPDBエントリー | 2O4H |
| 分子名称 | Aspartoacylase, ZINC ION, PHOSPHATE ION, ... (4 entities in total) |
| 機能のキーワード | canavan disease, n-acetyl-l-aspartate, zinc-dependent hydrolase, aspartoacylase family, aminoacylase-2, acy2, aspa, n-phosphonomethyl-l-aspartate, hydrolase |
| 由来する生物種 | Homo sapiens (human) |
| 細胞内の位置 | Cytoplasm: P45381 |
| タンパク質・核酸の鎖数 | 2 |
| 化学式量合計 | 72078.87 |
| 構造登録者 | Le Coq, J.,Pavlovsky, A.,Sanishvili, R.,Viola, R.E. (登録日: 2006-12-05, 公開日: 2007-11-06, 最終更新日: 2023-08-30) |
| 主引用文献 | Le Coq, J.,Pavlovsky, A.,Malik, R.,Sanishvili, R.,Xu, C.,Viola, R.E. Examination of the Mechanism of Human Brain Aspartoacylase through the Binding of an Intermediate Analogue. Biochemistry, 47:3484-3492, 2008 Cited by PubMed Abstract: Canavan disease is a fatal neurological disorder caused by the malfunctioning of a single metabolic enzyme, aspartoacylase, that catalyzes the deacetylation of N-acetyl-L-aspartate to produce L-aspartate and acetate. The structure of human brain aspartoacylase has been determined in complex with a stable tetrahedral intermediate analogue, N-phosphonomethyl-L-aspartate. This potent inhibitor forms multiple interactions between each of its heteroatoms and the substrate binding groups arrayed within the active site. The binding of the catalytic intermediate analogue induces the conformational ordering of several substrate binding groups, thereby setting up the active site for catalysis. The highly ordered binding of this inhibitor has allowed assignments to be made for substrate binding groups and provides strong support for a carboxypeptidase-type mechanism for the hydrolysis of the amide bond of the substrate, N-acetyl- l-aspartate. PubMed: 18293939DOI: 10.1021/bi702400x 主引用文献が同じPDBエントリー |
| 実験手法 | X-RAY DIFFRACTION (2.7 Å) |
構造検証レポート
検証レポート(詳細版)
をダウンロード






